review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Paul Devroey | Q7150251 |
Robert N. Taylor | Q50063528 | ||
Felice Petraglia | Q56628175 | ||
Paolo Vercellini | Q57008851 | ||
Thomas D'Hooghe | Q92610651 | ||
Lone Hummelshoj | Q94657080 | ||
B. C. J. M. Fauser | Q112562991 | ||
Vincenzo De Leo | Q45452591 | ||
P2093 | author name string | Paul G Mermelstein | |
Joop S E Laven | |||
Kelle H Moley | |||
Hilary O D Critchley | |||
Basil C Tarlatzis | |||
Luca Gianaroli | |||
Sarah L Berga | |||
Susan Rubin | |||
Angelique J Goverde | |||
P2860 | cites work | Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan | Q21245262 |
Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques | Q24542881 | ||
Clinical practice. Primary ovarian insufficiency | Q24653014 | ||
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk | Q28202563 | ||
Spatiotemporal coupling of focal extracellular matrix degradation and reconstruction in the menstrual human endometrium | Q30875482 | ||
Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits | Q30982554 | ||
Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis | Q33922773 | ||
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). | Q34285382 | ||
Loci at chromosomes 13, 19 and 20 influence age at natural menopause | Q34398729 | ||
IMS updated recommendations on postmenopausal hormone therapy | Q34626471 | ||
Vascular dysfunction and metabolic parameters in polycystic ovary syndrome | Q46471315 | ||
Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. | Q46497183 | ||
Cognitive impairment associated with adjuvant therapy in breast cancer | Q46647395 | ||
Quantitative expression of apoptosis-regulating genes in endometrium from women with and without endometriosis | Q47586464 | ||
Disordered meiotic regulation of oocytes by duration of diabetes mellitus in BBdp rat. | Q48777645 | ||
Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. | Q53541411 | ||
Polycystic Ovary Syndrome | Q56092373 | ||
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes | Q56989045 | ||
Developmental origin of polycystic ovary syndrome - a hypothesis | Q34721288 | ||
Non-genomic actions of androgens. | Q34727863 | ||
Consensus on infertility treatment related to polycystic ovary syndrome. | Q34744664 | ||
Emerging role of genomics in endometriosis research | Q34953119 | ||
Genetics of ovarian disorders: polycystic ovary syndrome | Q35668794 | ||
S-palmitoylation modulates estrogen receptor alpha localization and functions. | Q36308079 | ||
Endometrium in PCOS: Implantation and predisposition to endocrine CA. | Q36505888 | ||
Pregnancy complications in PCOS. | Q36505905 | ||
A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome | Q36557607 | ||
Plasma membrane estrogen receptors | Q36660250 | ||
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. | Q36758555 | ||
Endometriosis: cost estimates and methodological perspective | Q36856199 | ||
VEGF blockade inhibits angiogenesis and reepithelialization of endometrium | Q36879461 | ||
Polycystic ovary syndrome and pregnancy outcome: red herring or red flag? | Q36884181 | ||
Rapid actions of androgens | Q36993488 | ||
Decreased oocyte-granulosa cell gap junction communication and connexin expression in a type 1 diabetic mouse model | Q37060666 | ||
Nervous system physiology regulated by membrane estrogen receptors | Q37143039 | ||
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report | Q37308058 | ||
Maternal diabetes causes mitochondrial dysfunction and meiotic defects in murine oocytes | Q37369790 | ||
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. | Q37412812 | ||
Polycystic ovary syndrome, obesity and reproductive implications | Q37585306 | ||
Oestrogen and progesterone regulation of inflammatory processes in the human endometrium | Q37672732 | ||
Obesity, pregnancy, inflammation, and vascular function. | Q37705670 | ||
Metabolic impact of estrogen signalling through ERalpha and ERbeta | Q37769774 | ||
Primary ovarian insufficiency | Q37779848 | ||
A botanical extract from channel flow inhibits cell proliferation, induces apoptosis, and suppresses CCL5 in human endometriotic stromal cells | Q39983603 | ||
Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo | Q40483359 | ||
Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells | Q41674994 | ||
Sulindac suppresses nuclear factor-kappaB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis | Q42483929 | ||
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study | Q43043857 | ||
Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population | Q43271333 | ||
Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women | Q44582007 | ||
Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility | Q44615923 | ||
Coexpression of fractalkine and its receptor in normal human endometrium and in endometrium from users of progestin-only contraception supports a role for fractalkine in leukocyte recruitment and endometrial remodeling | Q45173635 | ||
Cortisol inactivation by 11beta-hydroxysteroid dehydrogenase-2 may enhance endometrial angiogenesis via reduced thrombospondin-1 in heavy menstruation | Q46154195 | ||
P433 | issue | 8 | |
P304 | page(s) | 702-712 | |
P577 | publication date | 2011-08-01 | |
P1433 | published in | Reproductive Sciences | Q7314305 |
P1476 | title | Sex steroid hormones and reproductive disorders: impact on women's health | |
P478 | volume | 18 |